A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage

被引：0
|
作者：
Zhou, Jian
Fan, Jia
Gu, Fang-Ming
Li, Tao
Bai, Dou-Sheng
Sun, Hui-Chuan
Wang, Zheng
Qiu, Shuang-Jian
Ye, Qing-Hai
Shi, Ying-Hong
Gao, Qiang
Wang, Xiao-Ying
Yang, Xin-Rong
Shi, Guo-Ming
Peng, Yuan-Fei
机构：
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Minist Educ, Shanghai, Peoples R China
[2] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China
[3] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Yangzhou Univ, Subei Peoples Hosp, Yangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4126
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
    Tian-Qi Zhang
    Zhi-Jun Geng
    Meng-Xuan Zuo
    Ji-Bin Li
    Jin-Hua Huang
    Zi-Lin Huang
    Pei-Hong Wu
    Yang-Kui Gu
    Signal Transduction and Targeted Therapy, 8
  • [22] Short-term preoperative treatment with sorafenib for patients with resectable hepatocellular carcinoma (HCC): results of the BIOSHARE neoadjuvant phase II study from GERCOR IRC
    Bouattour, Mohamed
    Fartoux, Laetitia
    Rosmorduc, Olivier
    Vibert, Eric
    Costentin, Charlotte E.
    Soubrane, Olivier
    Scatton, Olivier
    Ronot, Maxime
    Castera, Laurent
    Garnier, Muriel
    De Gramont, Armand
    Belghiti, Jacques
    Paradis, Valerie
    Tijeras-Raballand, Annemila
    Hadengue, Alexandra
    Brusquant, David
    Chibaudel, Benoist
    Raymond, Eric
    Faivre, Sandrine
    HEPATOLOGY, 2015, 62 : 420A - 420A
  • [23] Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
    Li, Dailong
    Xu, Lu
    Ji, Jinxing
    Bao, Dan
    Hu, Juan
    Qian, Ying
    Zhou, Yinjie
    Chen, Zhuo
    Li, Daojun
    Li, Xiaopeng
    Zhang, Xiaoling
    Wang, Hao
    Yi, Changjun
    Shi, Menglu
    Pang, Yaqi
    Liu, Siqi
    Xu, Xinhua
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] Updated results from phase II study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
    Zhang, H.
    Lu, W.
    Fu, Y.
    Li, J.
    Wang, J.
    Chen, Z.
    Ding, S.
    Chen, S.
    Huang, J.
    Zhai, J.
    Li, X.
    Yang, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1486 - S1486
  • [25] Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study
    Chen, Shiguang
    Zhang, Kongzhi
    Liu, Weifu
    Yu, Wenchang
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 90 - 98
  • [26] Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.
    Wu, Jia-Yi
    Fu, Yang-Kai
    Wen, Tianfu
    Wang, Shuang-Jia
    Chen, Jiafei
    Zhang, Zhibo
    Liu, Chongyuan
    Wang, Wei
    Fang, Lu
    Tang, Zhong
    Chen, Yufeng
    Yan, Maolin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 503 - 503
  • [27] Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial
    Zhao, H.
    Du, S.
    Zhu, Z.
    Jiang, L.
    Che, X.
    Qian, H.
    Song, J.
    Liu, D.
    Zhang, Y.
    Zhang, P.
    Sun, Y.
    Zhang, W.
    Tang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S873 - S873
  • [28] Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
    Mao, X.
    Duan, X.
    Wu, D.
    Zhou, C.
    Tian, Y.
    Shen, J.
    Xu, G.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
  • [29] Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Lai, Jianlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 494 - 494
  • [30] TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
    Huang, Z.
    Zhou, J.
    Yang, M.
    Zhang, W.
    Sun, Y.
    Lu, H.
    Wang, H.
    Bi, X.
    Zhang, Y.
    Zhao, J.
    Yang, Y.
    Zhang, B.
    Ye, F.
    Zhao, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1545 - S1545
12345